Navigation Links
Zafgen Secures $21 Million in Series D Financing
Date:12/4/2012

CAMBRIDGE, Mass., Dec. 4, 2012 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $21 million in a Series D equity financing. New investor, Alta Partners, a prominent venture capital firm in life sciences, leads the financing, joining existing investors Atlas Venture and Third Rock Ventures. Proceeds from the financing will be used to support the continued development of beloranib, the obesity therapeutic that is currently in phase 2a clinical development.

"We are thrilled to have attracted more world-class investors to our syndicate as we move forward with phase 2a clinical testing for beloranib," said Thomas Hughes, Ph.D., president and chief executive officer, Zafgen, Inc. "Alta Partners has a strong portfolio and consistent track record of recognizing and investing in high-growth firms.  We appreciate their confidence in the promise of beloranib to help address the unmet needs of severely obese patients."  

Beloranib utilizes a unique mechanism of action targeting Methionine Aminopeptidase 2 (MetAP2). The therapeutic is in development to assess potential to safely and rapidly reduce body weight by restoring balance between the production and utilization of fat.

On November 6, 2012, Zafgen announced the initiation of Phase 2a clinical testing of beloranib following the completion of three consecutive Phase 1b studies demonstrating rapid weight loss, reductions in body fat, improvements in cardiovascular risk factors and encouraging tolerability. The phase 2a clinical trial will evaluate weight loss, safety and pharmacokinetics of beloranib administered twice a week. Results from this study are anticipated to be available in June, 2013. 

"We are impressed with Zafgen's leadership and efficient business approach and encouraged by early results with beloranib," said Ed Hurwitz, director a
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Delcath Systems, Inc. Secures $20 Million Credit Facility
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Benvenue Medical Secures $25 Million Series D Financing
5. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
6. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
7. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
8. BioMotiv Secures $21 million in Initial Funding
9. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
10. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
11. Flexion Therapeutics Secures $20 Million in Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 15, 2011 XTIO2 INC . ... the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM ... XTI™  Nano-Facemask . It is the world,s most ... transmitted via air and contact surfaces. The unique nanocoating ...
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading ... disorders, today announced that researchers at Samuel Merritt University ... Grant to study the effects of wearing a strategically ... with MS. This grant comes after ...
Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
(Date:4/22/2014)... release is available in German . ... important intracellular signaling molecules, but their mode of action ... of cellular function and behavior, while at high concentrations ... and DNA. To analyze how redox signaling unfolds in ... microscopy technique has been developed jointly by the teams ...
(Date:4/22/2014)... help rein in massive health care spending, a new ... find ways to incentivize pharmaceutical companies and device makers ... of examining existing medical technologies and their use, a ... what drugs and medical devices get created in the ... care spending with as little loss of health as ...
(Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
(Date:4/22/2014)... demonstrated the first size-based form of chromatography that ... living cells. This unique physical approach to probing ... whether a cell lives or dies, remains normal ... conventional microscopy. , "We,ve developed membrane-embedded nanodot array ... probe and manipulate membrane assemblies, including signaling clusters, ...
(Date:4/22/2014)... release is available in German . ... Laboratories of the University of Vienna and the Medical University ... now shown how double stranded RNA, such as viral genetic ... During the immune response against viral infection, the protein ADAR1 ... it modifies viral RNA to inhibit reproduction of the virus. ...
Breaking Medicine News(10 mins):Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... known to be harmful. Some of them like malaria can ... make the host female less fertile. A recent study has ... The vivacious Wolbachia is actually giving the host a boost ... ,This new study reveals the Symbiotic or mutually ...
... of the transgender community in India is highly aware of ... a survey by a Chennai-based NGO. ,"Most ... transmitted diseases and AIDS. As much as 99 percent said ... said they used condoms during sexual activity," said R. Isabel, ...
... help cut back on how much food and calories you eat ... show that when participants in the study ate a first course ... intake at lunch by 20 percent, compared to when they did ... studies about consuming lower-calorie soup as a way to reduce food ...
... are no more likely than other children to have ... ,Researchers compared blood samples of 34 children with autism ... been referred to an outpatient clinic of the same ... detect celiac diseaseanti-gliadin antibodies and anti-endomysial antibodies. Biopsies of ...
... improve symptoms of moderate to severe chronic obstructive pulmonary ... ,The results of the randomized, double-blind, ... issue of the May American Journal of Respiratory and ... ,According to an editorial commenting on the ...
... A study finds that sleep deprivation can adversely affect ... the expectation of gains and making light of ... understand the neural underpinnings of risky decision making under ... Duke University studied healthy volunteers as they underwent functional ...
Cached Medicine News:Health News:Useful Parasites 2Health News:Awareness About HIV/AIDS is High Among the Transgenders: Survey 2Health News:Taking Low-calorie Soup Before Meal Will Help Cut Calories at Meals 2Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Sleep Deprivation can Affect Competent Decision-making 2
REFRESH TEARS® lubricating eye drops does more than just smoothe and relieve dry, irritated eyes. REFRESH TEARS® creates a shield of protection against further irritation with its unique, lon...
... feel dry, scratchy, or irritated, you want ... REFRESH PLUS® lubricant eye drops for mild ... what youre looking for. A couple of ... crave with a special formula that has ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
...
Medicine Products: